The aim of this study was to determine the size-dependent penetration ability of gold nanoparticles and the potential application of ultrasmall gold nanoparticles for intranucleus delivery and therapy. We synthesized gold nanoparticles with diameters of 2, 6, 10, and 16 nm and compared their intracellular distribution in MCF-7 breast cancer cells. Nanoparticles smaller than 10 nm (2 and 6 nm) could enter the nucleus, whereas larger ones (10 and 16 nm) were found only in the cytoplasm. We then investigated the possibility of using ultrasmall 2 nm nanoparticles as carriers for nuclear delivery of a triplex-forming oligonucleotide (TFO) that binds to the c-myc promoter. Compared to free TFO, the nanoparticle-conjugated TFO was more effective at reducing c-myc RNA and c-myc protein, which resulted in reduced cell viability. Our result demonstrated that the entry of gold nanoparticles into the cell nucleus is critically dependent on the size of the nanoparticles. We developed a strategy for regulating gene expression, by directly delivering TFOs into the nucleus using ultrasmall gold nanoparticles. More importantly, guidelines were provided to choose appropriate nanocarriers for different biomedical purposes.
Nanosized
objects, such as nanoparticles and other drug carriers
used in nanomedicine, once in contact with biological environments
are modified by adsorption of biomolecules on their surface. The presence
of this corona strongly affects the following interactions at cell
and organism levels. It has been shown that corona proteins can be
recognized by cell receptors. However, it is not known whether the
composition of this acquired layer can also affect the mechanisms
nanoparticles use to enter cells. This is of particular importance
when considering that the same nanoparticles can form different coronas
for instance in vitro when exposed to cells in different
serum amounts or in vivo depending on the exposure
or administration route. Thus, in this work, different coronas were
formed on 50 nm silica by exposing them to different serum concentrations.
The uptake efficiency in HeLa cells was compared, and the uptake mechanisms
were characterized using transport inhibitors and RNA interference.
The results showed that the nanoparticles were internalized by cells via different mechanisms when different coronas were formed,
and only for one corona condition was uptake mediated by the LDL receptor.
This suggested that coronas of different composition can be recognized
differently by cell receptors, and this in turn leads to internalization via different mechanisms. Similar studies were performed
using other cells, including A549 cells and primary HUVEC, and different
nanoparticles, namely 100 nm liposomes and 200 nm silica. Overall,
the results confirmed that the corona composition can affect the mechanisms
of nanoparticle uptake by cells.
The structural arrangement of amino acid residues in a native enzyme provides a blueprint for the design of artificial enzymes. One challenge of mimicking the catalytic center of a native enzyme is how to arrange the essential amino acid residues in an appropriate position. In this study, we designed an artificial hydrolase via self-assembly of short peptides to catalyze ester hydrolysis. When the assembled hydrolase catalytic sites were embedded in a matrix of peptide nanofibers, they exhibited much higher catalytic efficiency than the peptide nanofibers without the catalytic sites, suggesting that this well-ordered nanostructure is an attractive scaffold for developing new artificial enzymes. Furthermore, the cytotoxicity of the assembled hydrolase was evaluated with human cells, and the novel artificial biological enzyme showed excellent biocompatibility.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.